The global sofosbuvir/ledipasvir compound drugs market is expected to grow at a CAGR of around 8.5% during the forecast period, from 2021 to 2030. The growth in this market can be attributed to the increasing prevalence of chronic hepatitis C virus (HCV) infection and the high cost of treatment with direct acting antiviral agents. The global sofosbuvir/ledipasvir compound drugs market is segmented on the basis of type, application, and region. On the basis of type, it is segmented into bottled packaging and film coated packaging. On the basis of application, it is segmented into HCV genotype 1, HCV genotype 3, and HCV genotype 4.On the basis of region, it is segmented into North America (NA), Latin America (LA), Europe (EU), Asia Pacific (APAC) and Middle East & Africa (MEA). North America accounted for a major share in terms of revenue in 2016 owing to its large population size as well as high prevalence rates for chronic hepatitis C virus infection among adults aged 18 years or older. In addition to this factor, there are also higher rates for new cases reported annually in North America than any other region globally which has led to an increase in demand for sofosbuvir/ledipasvir compound drugs over time. -The global Sofosbuvir/Ledipasvir Compound Drugs market is expected to grow at a CAGR of around 8.5% during the forecast period. -The global Sofosbuvir/Ledipasvir Compound Drugs market is expected to reach USD 3,890 million by 2023 from USD 2,700 million in 2017. -Increasing prevalence of chronic hepatitis C and increasing number of patients with HCV infection are the major drivers for the growth of this market.
Industry Growth Insights published a new data on “Sofosbuvir/Ledipasvir Compound Drugs Market”. The research report is titled “Sofosbuvir/Ledipasvir Compound Drugs Market research by Types (Bottled Packaging, Film Coated Packaging), By Applications (Hepatitis C Virus (HCV) Genotype 1, Hepatitis C Virus (HCV) Genotype 3, Hepatitis C Virus (HCV) Genotype 4, Other), By Players/Companies Gilead Sciences, Natco Ltd, Zydus Cadila, Hetero Drugs, Dr Reddy's Laboratories, Sun Pharmaceutical Industries, Cipla, Abbott, Biocon, Torrent Pharmaceuticals, Lupin Ltd”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Sofosbuvir/Ledipasvir Compound Drugs Market Research Report
By Type
Bottled Packaging, Film Coated Packaging
By Application
Hepatitis C Virus (HCV) Genotype 1, Hepatitis C Virus (HCV) Genotype 3, Hepatitis C Virus (HCV) Genotype 4, Other
By Companies
Gilead Sciences, Natco Ltd, Zydus Cadila, Hetero Drugs, Dr Reddy's Laboratories, Sun Pharmaceutical Industries, Cipla, Abbott, Biocon, Torrent Pharmaceuticals, Lupin Ltd
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
238
Number of Tables & Figures
167
Customization Available
Yes, the report can be customized as per your need.
Global Sofosbuvir/Ledipasvir Compound Drugs Market Report Segments:
The global Sofosbuvir/Ledipasvir Compound Drugs market is segmented on the basis of:
Types
Bottled Packaging, Film Coated Packaging
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hepatitis C Virus (HCV) Genotype 1, Hepatitis C Virus (HCV) Genotype 3, Hepatitis C Virus (HCV) Genotype 4, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Gilead Sciences
- Natco Ltd
- Zydus Cadila
- Hetero Drugs
- Dr Reddy's Laboratories
- Sun Pharmaceutical Industries
- Cipla
- Abbott
- Biocon
- Torrent Pharmaceuticals
- Lupin Ltd
Highlights of The Sofosbuvir/Ledipasvir Compound Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Bottled Packaging
- Film Coated Packaging
- By Application:
- Hepatitis C Virus (HCV) Genotype 1
- Hepatitis C Virus (HCV) Genotype 3
- Hepatitis C Virus (HCV) Genotype 4
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Sofosbuvir/Ledipasvir Compound Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Sofosbuvir/ledipasvir is a combination drug that inhibits the replication of the hepatitis C virus.
Some of the major players in the sofosbuvir/ledipasvir compound drugs market are Gilead Sciences, Natco Ltd, Zydus Cadila, Hetero Drugs, Dr Reddy's Laboratories, Sun Pharmaceutical Industries, Cipla, Abbott, Biocon, Torrent Pharmaceuticals, Lupin Ltd.
The sofosbuvir/ledipasvir compound drugs market is expected to register a CAGR of 8.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Sofosbuvir/Ledipasvir Compound Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Sofosbuvir/Ledipasvir Compound Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Sofosbuvir/Ledipasvir Compound Drugs Market - Supply Chain
4.5. Global Sofosbuvir/Ledipasvir Compound Drugs Market Forecast
4.5.1. Sofosbuvir/Ledipasvir Compound Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Sofosbuvir/Ledipasvir Compound Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Sofosbuvir/Ledipasvir Compound Drugs Market Absolute $ Opportunity
5. Global Sofosbuvir/Ledipasvir Compound Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Sofosbuvir/Ledipasvir Compound Drugs Market Size and Volume Forecast by Type
5.3.1. Bottled Packaging
5.3.2. Film Coated Packaging
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Sofosbuvir/Ledipasvir Compound Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Sofosbuvir/Ledipasvir Compound Drugs Market Size and Volume Forecast by Application
6.3.1. Hepatitis C Virus (HCV) Genotype 1
6.3.2. Hepatitis C Virus (HCV) Genotype 3
6.3.3. Hepatitis C Virus (HCV) Genotype 4
6.3.4. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Sofosbuvir/Ledipasvir Compound Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Sofosbuvir/Ledipasvir Compound Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Sofosbuvir/Ledipasvir Compound Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Sofosbuvir/Ledipasvir Compound Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Sofosbuvir/Ledipasvir Compound Drugs Demand Share Forecast, 2019-2026
9. North America Sofosbuvir/Ledipasvir Compound Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Sofosbuvir/Ledipasvir Compound Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Sofosbuvir/Ledipasvir Compound Drugs Market Size and Volume Forecast by Application
9.4.1. Hepatitis C Virus (HCV) Genotype 1
9.4.2. Hepatitis C Virus (HCV) Genotype 3
9.4.3. Hepatitis C Virus (HCV) Genotype 4
9.4.4. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Sofosbuvir/Ledipasvir Compound Drugs Market Size and Volume Forecast by Type
9.7.1. Bottled Packaging
9.7.2. Film Coated Packaging
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Sofosbuvir/Ledipasvir Compound Drugs Demand Share Forecast, 2019-2026
10. Latin America Sofosbuvir/Ledipasvir Compound Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Sofosbuvir/Ledipasvir Compound Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Sofosbuvir/Ledipasvir Compound Drugs Market Size and Volume Forecast by Application
10.4.1. Hepatitis C Virus (HCV) Genotype 1
10.4.2. Hepatitis C Virus (HCV) Genotype 3
10.4.3. Hepatitis C Virus (HCV) Genotype 4
10.4.4. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Sofosbuvir/Ledipasvir Compound Drugs Market Size and Volume Forecast by Type
10.7.1. Bottled Packaging
10.7.2. Film Coated Packaging
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Sofosbuvir/Ledipasvir Compound Drugs Demand Share Forecast, 2019-2026
11. Europe Sofosbuvir/Ledipasvir Compound Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Sofosbuvir/Ledipasvir Compound Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Sofosbuvir/Ledipasvir Compound Drugs Market Size and Volume Forecast by Application
11.4.1. Hepatitis C Virus (HCV) Genotype 1
11.4.2. Hepatitis C Virus (HCV) Genotype 3
11.4.3. Hepatitis C Virus (HCV) Genotype 4
11.4.4. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Sofosbuvir/Ledipasvir Compound Drgs Market Size and Volume Forecast by Type
11.7.1. Bottled Packaging
11.7.2. Film Coated Packaging
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Sofosbuvir/Ledipasvir Compound Drugs Demand Share, 2019-2026
12. Asia Pacific Sofosbuvir/Ledipasvir Compound Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Sofosbuvir/Ledipasvir Compound Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Sofosbuvir/Ledipasvir Compound Drugs Market Size and Volume Forecast by Application
12.4.1. Hepatitis C Virus (HCV) Genotype 1
12.4.2. Hepatitis C Virus (HCV) Genotype 3
12.4.3. Hepatitis C Virus (HCV) Genotype 4
12.4.4. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Sofosbuvir/Ledipasvir Compound Drugs Market Size and Volume Forecast by Type
12.7.1. Bottled Packaging
12.7.2. Film Coated Packaging
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Sofosbuvir/Ledipasvir Compound Drugs Demand Share, 2019-2026
13. Middle East & Africa Sofosbuvir/Ledipasvir Compound Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Sofosbuvir/Ledipasvir Compound Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Sofosbuvir/Ledipasvir Compound Drugs Market Size and Volume Forecast by Application
13.4.1. Hepatitis C Virus (HCV) Genotype 1
13.4.2. Hepatitis C Virus (HCV) Genotype 3
13.4.3. Hepatitis C Virus (HCV) Genotype 4
13.4.4. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Sofosbuvir/Ledipasvir Compound Drugs Market Size and Volume Forecast by Type
13.7.1. Bottled Packaging
13.7.2. Film Coated Packaging
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Sofosbuvir/Ledipasvir Compound Drugs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Sofosbuvir/Ledipasvir Compound Drugs Market: Market Share Analysis
14.2. Sofosbuvir/Ledipasvir Compound Drugs Distributors and Customers
14.3. Sofosbuvir/Ledipasvir Compound Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Gilead Sciences
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Natco Ltd
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Zydus Cadila
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Hetero Drugs
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Dr Reddy's Laboratories
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Sun Pharmaceutical Industries
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Cipla
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Abbott
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Biocon
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Torrent Pharmaceuticals
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Lupin Ltd
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook